Patients who are getting immune globulin for the first time ... Lab and/or medical tests (such as IgG levels, complete blood count) should be performed periodically to monitor your progress.

The dosage is based on your medical condition, weight, and response to treatment. If you have primary immune deficiency and respond well to this medication, your doctor may allow you to give this ...

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied to the overactivity of antibodies. Published in the journal, Cell01135-8?

Antibodies are part of a large family of chemicals called immunoglobulins, which play many roles in the immune response: Immunoglobulin G (IgG) marks microbes so other cells can recognize and deal ...

A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary endpoint. But, having made a second-generation molecule its lead candidate last year, the biotech isn’t currently ...

Laminin β4 IgG Drives Tissue Damage in Anti-p200 Pemphigoid and Shows Interactions with Laminin α3 and γ1/2 Chains,” ...

protease targeting IgG autoantibodies for the treatment of autoimmune diseases. The study will build on preclinical evidence of S‑1117’s rapid, deep, and sustained reduction of IgG levels ...

Asthma is a chronic lung disease caused by an immune response. However, it is not considered an autoimmune disease. Asthma is inflammation of the airways that carry air to and from the lungs.

In the human, the placenta is the predominant route of IgG transfer in the maternal-to-fetal direction; the immune protection provided by maternal antibodies is essential for newborns during the ...

Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP ...